Evidence map›Paper›PMID 31366217›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2019

Ly6C

Pu Fang 方璞, Xinyuan Li 李欣源, Huimin Shan 单慧敏, Jason J Saredy, Ramon Cueto, Jixiang Xia 夏继祥, Xiaohua Jiang 蒋晓华, Xiao-Feng Yang 杨晓峰, Hong Wang 王虹

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. 29 mJournal of immunology research · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pu Fang 方璞From the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Xinyuan Li 李欣源Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia (X.L.).
Huimin Shan 单慧敏From the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Jason J SaredyFrom the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Ramon CuetoFrom the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Jixiang Xia 夏继祥From the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Xiaohua Jiang 蒋晓华From the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Xiao-Feng Yang 杨晓峰From the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Hong Wang 王虹From the Center for Metabolic Disease Research (P.F., H.S., J.J.S., R.C., J.X., X.J., X.-F.Y., H.W.), Lewis Kats School of Medicine, Temple University, Philadelphia, PA.
Temple University · US

Funding

HEMATOPOIESIS TRAINING GRANTT32DK007780 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI TONG, WEI · 1999 to 2023
$6.7M
Atherogenic mechanisms with homocysteineR01HL077288 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2004 to 2014
$3.8M
CD40 monocyte in chronic kidney diseaseR01DK113775 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2017 to 2021
$3.3M
Inhibition of Endothelial Growth by HomocysteineR01HL067033 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2002 to 2011
$3.0M
Hyperhomocysteinemia and HDL MetabolismR01HL117654 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2013 to 2017
$3.0M
Caspase-1 activation mediates chronic kidney disease-accelerated atherosclerosisR01HL131460 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI CHOI, ERIC T., WANG, HONG · 2016 to 2019
$2.8M
The roles of miR-155 in regulating atherosclerosis and metabolically healthy obesityR01HL138749 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2017 to 2020
$2.6M
IL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activationR01HL147565 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2019 to 2022
$2.6M
NADHP Oxidase-mediated MC differentiation & Endothelial Dysfunction in HHcyR01HL110764 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2011 to 2015
$2.5M
Atherogenic roles of complement systemR01HL130233 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI QIN, XUEBIN, WANG, HONG · 2016 to 2019
$2.5M
IL-35 suppression of endothelial cell activation and atherosclerosisR01HL132399 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2017 to 2020
$2.3M
HHcy-induced Inflammatory Monocyte and Macrophage Differentiation in DiabetesR01DK104116 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2015 to 2019
$2.2M
NHLBI NIH HHS R01 HL067033NHLBI NIH HHS R01 HL077288NHLBI NIH HHS R01 HL082774NHLBI NIH HHS R01 HL110764NHLBI NIH HHS R01 HL117654NHLBI NIH HHS R01 HL130233NHLBI NIH HHS R01 HL131460NHLBI NIH HHS R01 HL132399NHLBI NIH HHS R01 HL138749NHLBI NIH HHS R01 HL147565NIDDK NIH HHS R01 DK104116NIDDK NIH HHS R01 DK113775NIDDK NIH HHS T32 DK007780
6 · The paper itself

Abstract

objectiveHyperhomocysteinemia (HHcy) is a potent risk factor for diabetic cardiovascular diseases. We have previously reported that hyperhomocysteinemia potentiates type 1 diabetes mellitus-induced inflammatory monocyte differentiation, vascular dysfunction, and atherosclerosis. However, the effects of hyperhomocysteinemia on vascular inflammation in type 2 diabetes mellitus (T2DM) and the underlying mechanism are unknown. Approach and Results: Here, we demonstrate that hyperhomocysteinemia was induced by a high methionine diet in control mice (homocysteine 129 µmol/L), which was further worsened in T2DM db/db mice (homocysteine 180 µmol/L) with aggravated insulin intolerance. Hyperhomocysteinemia potentiated T2DM-induced mononuclear cell, monocyte, inflammatory monocyte (CD11b

conclusionsHyperhomocysteinemia potentiated systemic and vessel wall inflammation and vascular dysfunction partially via inflammatory monocyte subset induction in T2DM. Inflammatory monocyte may be a novel therapeutic target for insulin resistance, inflammation, and cardiovascular complications in hyperhomocysteinemia+T2DM.

Indexed as

AnimalsAntigens, LyAtherosclerosisCell DifferentiationDiabetes Mellitus, Type 2Disease Models, AnimalEndothelium, VascularFemaleHyperhomocysteinemiaInsulinInsulin ResistanceMacrophagesMiceMonocytesRandom AllocationRisk FactorsAntigens, LyInsulinLy-6C antigen, mousecardiovascular diseasesdiabetes mellitushyperhomocysteinemiainflammationmonocytes

Identifiers

PMID31366217
PMCPMC6761027
OpenAlexW2965649603

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.